4/A: Stoke Therapeutics CEO Awarded Performance Stock Units, Amended Filing Corrects Vesting Details
SEC Form 4 Amendment
Stoke Therapeutics CEO Edward M. Kaye received performance-based restricted stock units, with an amended filing correcting the number of units awarded and vested.
Summary
- Stoke Therapeutics CEO, Edward M. Kaye, was granted performance-based restricted stock units.
- The award was granted on December 3, 2024, with half vesting on the same date and the remainder vesting on December 3, 2025.
- The vesting is contingent upon the CEO's continued service to the company.
- An amended filing was made to correct the number of performance-based restricted stock units awarded and vested on December 3, 2024.
- The amendment also corrected the reporting person's total securities held.
Sentiment
Score: 7
Explanation: The document is a routine filing regarding executive compensation, which is generally viewed positively as it aligns management's interests with shareholders. The amendment indicates a correction, which is neutral.
Positives
- The performance-based stock units align the CEO's interests with the company's performance.
- The vesting schedule provides an incentive for continued service.
Risks
- The vesting of the stock units is contingent on the CEO's continued service, which could be a risk if the CEO were to leave the company before the vesting dates.
Industry Context
This type of equity-based compensation is common for CEOs in the biotechnology industry to align their interests with shareholders and incentivize performance.
Comparison to Industry Standards
- Performance-based stock unit awards are a standard practice for executive compensation in the biotech industry.
- Companies like BioMarin Pharmaceutical and Vertex Pharmaceuticals also use similar equity-based compensation structures for their executives.
- The vesting schedule of half the award vesting after one year and the remainder after two years is also a common practice.
Stakeholder Impact
- Shareholders may view the performance-based stock units positively as they align the CEO's interests with the company's performance.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 2024-12-03 | Date of the performance stock unit award and initial vesting of half the units. |
| 2024-12-05 | Date of the original filing. |
| 2024-12-10 | Date of the amended filing. |
| 2025-12-03 | Date of the second vesting of the remaining performance stock units. |
Keywords
Performance Stock Units, Restricted Stock Units, CEO Compensation, Stock Vesting, Stoke Therapeutics, Equity Award
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.